An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Latest Information Update: 09 May 2024
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors Shire; Takeda
Most Recent Events
- 06 May 2024 Status changed from active, no longer recruiting to completed.
- 15 Apr 2024 Planned End Date changed from 29 Mar 2024 to 30 Apr 2024.
- 15 Apr 2024 Planned primary completion date changed from 29 Mar 2024 to 30 Apr 2024.